Posted inBiotechnology
How Unlearn is building a scientific intelligence layer for clinical development
Sponsored By Unlearn Jun 8, 2026 8:00am Artificial intelligence is moving from a peripheral tool in clinical development into the…
Posted inBiotechnology
Ascidian, Lilly ink RNA exon editing pact worth up to $1.9B for genetic kidney diseases
“We can probably edit almost any gene, but that doesn’t mean we should,” Dan Rosan, chief financial and business officer…
Posted inBiotechnology
Visual Cues Shape Brain Networks After ACL Surgery
In an era where sports science and neurorehabilitation increasingly intersect, a groundbreaking study published in Scientific Reports is reshaping our…
Posted inBiotechnology
Travere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases
Travere Therapeutics has set its sights on Everest Medicines' therapy for rare kidney diseases, paying $112.5 million upfront for a…
Posted inBiotechnology
Student-Athletes’ Struggle: Inside Their Sleep Challenges
In the high-stakes world of student athletics, where physical prowess and mental acuity are demanded in equal measure, sleep is…
Posted inBiotechnology
New heights for NewLimit as anti-aging biotech nabs $435M to rejuvenate old cells
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-ready candidate years…
Posted inBiotechnology
Experimental Molecule “Reprograms” Brain’s Defenses to Combat Alzheimer’s Disease
In a groundbreaking advancement in Alzheimer’s disease research, scientists have unveiled a novel experimental molecule that “reprograms” the brain’s immune…
Posted inBiotechnology
Fulcrum scraps SCD program, considers options after FDA takes hard line on safety risks
Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the…
Posted inBiotechnology
How Screens Are Reshaping Childhood: New Research Reveals the Developing Brain Integrates Experience Until Age 25, Impacting Mental Health Deeply
In an era where digital screens have become ever-present in the lives of children and adolescents, a groundbreaking neuroscientific framework…
Posted inBiotechnology
Praxis pauses one of its seizure programs after phase 2 fail
Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in…